Abstract. This regulatory note supports the previous findings that suggest that the software package Kinetica, up to version 5.0.10, provides incorrect results for the 90% confidence intervals for the ratio test/reference where the groups are imbalanced in 2×2 crossover designs and parallel designs. The incorrect calculation results from using the simplified formula that is shown as an example in the Canadian guideline for a balanced dataset, but which provides an erroneous point estimate and confidence interval width in cases of imbalanced designs. Importantly, this software is rarely used for regulatory submissions in the European Union according to the search conducted in the Spanish Agency for Medicines and Health Care Products. According to our data, the error is minor if the imbalance between groups is small. However, the error may be relevant if the sample size is small and the imbalance is large. Therefore, bioequivalence studies should be reanalyzed by regulatory agencies to confirm the submitted results.
Schütz et al. (1, 2) have identified that the software Kinetica (version 5.0.10, Thermo Fisher Scientific 2007) provides incorrect 90% confidence intervals for the ratio of test/reference where the groups are imbalanced in two-sequence two-period crossover designs (1) and parallel designs (2) .
The authors suggest that this problem seems to be caused by the use of a simplified formula that implies that the sample size is equal in either sequences or groups. Consequently, the width of the confidence interval is different from the correct result obtained when one employs the formula that considers the sample size for each sequence or group differently. Furthermore, the point estimate is also biased because, according to the authors, it might reflect the means of logarithmized raw treatments values rather than using the treatment effects that arise from minimizing the sums of squares.
The authors state that they would appreciate feedback from other users of Kinetica. In this regard, as bioequivalence assessors in a regulatory agency, we noticed that Kinetica provides incorrect results before 2000, when one of us started to assess bioequivalence studies. We simply noticed that Kinetica employs the calculations as described in the example of the 1992 Canadian guideline for a balanced study (3) that is included again in the new 2012 Canadian guideline (4) . The point estimate was incorrect for crossover designs because the calculation ignored the sequence where the observations come from. The point estimate was calculated with arithmetic means (i.e. the mean of all observations of test and reference irrespective of sequence) instead of the least square mean, marginal mean or adjusted mean (the mean of the means of observations in each sequence) (5) . Both means, arithmetic and least square means, agree when studies are balanced. Therefore, it is biased only for imbalanced designs. Of course, the point estimate is not biased in parallel designs because in this case there are no sequences of administration. Then, in parallel designs, the only problem is the calculation of the width of the confidence interval, as these authors have shown (2) .
Some may be concerned that Kinetica is a commonly used statistical package and, therefore, numerous marketing authorisations could have been issued for which the underlying dossiers contain incorrectly calculated confidence intervals. However, a review of the bioequivalence assessment reports from before 2000 up to today elaborated in Spain by the regulatory agency, Agencia Española de Medicamentos y Productos Sanitarios, which include the software package employed for pharmacokinetic and statistical calculations, alleviates these concerns. A review of all national applications, centralised and decentralised or mutual recognition applications in which Spain was concerned (please note that Spain reassesses for consistency all bioequivalence studies even if they have been already assessed by the reference member State) produced the following observations: a) Kinetica has never been used in the statistical analysis of a bioequivalence study with a parallel design. b) Kinetica has been used only for the statistical analysis of 21 bioequivalence studies during all of these years.
Therefore, at least for Spain, it is inaccurate to consider that Kinetica is a commonly used statistical package or one of the most commonly used packages. Furthermore, these 21 studies were submitted in 18 applications out of 18,000 applications approximately. Thirteen studies supported the approval of 12 applications and eight were not accepted. Four accepted studies were balanced while nine accepted studies were imbalanced. Six of these imbalanced studies were assessed in national applications, one in a mutual recognition procedure and two in decentralised procedures. In the mutual recognition procedure assessed in 2004, the company was asked by us to submit the correct statistical analysis, since Spain can only recognise the previous authorisation granted by the reference member State. In the other eight studies, the reanalysis was conducted by the Spanish agency with SAS (see Table I ). Due to a small imbalance, the results were almost identical and the bioequivalence conclusion was not altered after the correct statistical analysis. Therefore, this issue cannot be considered a significant problem from a regulatory point of view.
It is possible that a failed study based on the original analysis could have been able to demonstrate bioequivalence with the correct statistical analysis, because we did not reanalyse the failed studies, but that cannot be considered a risk for the patients.
In one rejected study, the imbalance was notable because the subjects had been randomised completely at random, whereas bioequivalence studies are generally randomised in blocks. In fact, this is the only bioequivalence study that we have ever seen without block randomisation. Consequently, the sequences were initially imbalanced and the drop-outs occurred more frequently in the sequence with fewer subjects. Finally, the imbalance was 18 subjects in one sequence and nine subjects in the other sequence. Due to the small sample size (n=27) and the notable imbalance (18/9), the point estimate bias was significant (from 92.70 to 80.62%), but in both cases the 90% confidence interval was outside the acceptance limits. This scenario of a limited sample size with such notable imbalance is very unlikely. This low probability together with the infrequent use of this software package makes this issue very unlikely to have any clinical relevance.
Finally, in other regulatory jurisdictions like the USA or Canada all bioequivalence studies are reanalyzed from the raw data and, therefore, the software employed by the applicant/CRO is irrelevant and this deficiency does not affect these countries. Certainly, this example should be followed by all regulatory agencies.
